The following eligibility criteria below pertain to patients enrolling into Part 2B of the
        study.

        Inclusion Criteria:

          -  Have a known deleterious BRCA mutation (gBRCA or sBRCA) (as determined by a local
             laboratory that has received an international or country-specific, quality standards
             certification)

          -  Have evidence of measurable disease as defined by RECIST Version 1.1

          -  Have sufficient archival FFPE tumor tissue available for planned analyses. Archival
             tissue from the most recently collected biopsy or debulking surgery should be
             provided, if available.

          -  Have a histologically confirmed diagnosis of high-grade epithelial ovarian, fallopian
             tube, or primary peritoneal cancer

          -  Have received at least three prior chemotherapy regimens and have relapsed disease
             confirmed by radiologic assessment

        Exclusion Criteria:

          -  Active second malignancy, i.e., patient known to have potentially fatal cancer present
             for which she may be (but not necessarily) currently receiving treatment

             a. Patients with a history of malignancy that has been completely treated, with no
             evidence of that cancer currently, are permitted to enroll in the trial provided all
             chemotherapy was completed >6 months prior and/or bone marrow transplant (BMT) >2
             years prior to first dose of rucaparib

          -  Prior treatment with any PARP inhibitor.

          -  Untreated or symptomatic central nervous system (CNS) metastases. Patients with
             asymptomatic CNS metastases are eligible provided they have been clinically stable for
             at least 4 weeks.

          -  Received treatment with chemotherapy, radiation, antibody therapy or other
             immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental
             drugs 14 days prior to first dose of rucaparib and/or ongoing adverse effects from
             such treatment > NCI CTCAE Grade 1 (Grade 2 non-hematologic toxicity to most recent
             treatment may be permitted with prior advanced approval from Sponsor).

          -  Hospitalization for bowel obstruction within 3 months prior to enrollment.